BridgeMD
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
EU CTIS ID: 2023-505530-10-00
What this study is testing
To collect long-term follow-up data on delayed adverse events after administration of cilta-cel, and to characterize and understand the long-term safety profile of cilta-cel.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- All subjects who received cilta-cel in a Company-sponsored clinical study are candidates for Study MMY4002. The inclusion criteria for the study are described below: 1. Subjects who have received at least one dose of cilta-cel in a Company-sponsored clinical study.
- 2. Subjects who have provided informed consent for Study MMY4002.
You likely can't join if
- No exclusion criteria are applicable in this study.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Saudi Arabia
- Israel
- China
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Saudi Arabia; Israel; China; Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.